Compared with docetaxel, avelumab did not improve overall survival in patients with PD-L1-positive NSCLC previously treated with platinum-based chemotherapy [1,2,3,4,5,6,7,8,9,10,11,12,13,14]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.